Otherwise, it is questionable if a regimen with low rates of severe or long-lasting neutropenia, as ABVD is, can benefit from anti-microbial prophylaxis in place of G-CSF support if neutropenia occurs. The gene discussed is CSF3; the disease is neutropenia.